Serina Therapeutics entered a Securities Purchase Agreement on March 17, 2026, for a private placement issuing common stock or pre-funded warrants at $2.25 per share and redeemable warrants, with $15 million initial closing funded as of March 20, 2026, and up to $30 million total. Greg Bailey was appointed Co-Chairman of the Board effective upon initial closing.
Key takeaways
Securities Purchase Agreement dated March 17, 2026, led by Greg Bailey with other investors
$15.0 million initial tranche funded as of March 20, 2026
Additional tranches: minimum $5.0 million within 20 days, up to $15.0 million total $30 million
Securities priced at $2.25 per Common Stock share ($2.2499 per Pre-Funded Warrant)
Redeemable Warrants for 50% of shares at $5.00 exercise price, 4-year term, exercisable after 6 months
Greg Bailey appointed Co-Chairman alongside Balkrishan Gill, effective upon initial closing